Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02819804
Title Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Northwestern University

acute lymphoblastic leukemia


Dasatinib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.